{Reference Type}: Journal Article
{Title}: Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC.
{Author}: Mirzapoiazova T;Tseng L;Mambetsariev B;Li H;Lou CH;Pozhitkov A;Ramisetty SK;Nam S;Mambetsariev I;Armstrong B;Malhotra J;Arvanitis L;Nasser MW;Batra SK;Rosen ST;Wheeler DL;Singhal SS;Kulkarni P;Salgia R;
{Journal}: iScience
{Volume}: 27
{Issue}: 6
{Year}: 2024 Jun 21
{Factor}: 6.107
{DOI}: 10.1016/j.isci.2024.110132
{Abstract}: Although up to 80% small cell lung cancer (SCLC) patients' response is good for first-line chemotherapy regimen, most patients develop recurrence of the disease within weeks to months. Here, we report cytostatic effect of leflunomide (Leflu) and teriflunomide (Teri) on SCLC cell proliferation through inhibition of DRP1 phosphorylation at Ser616 and decreased mitochondrial fragmentation. When administered together, Teri and carboplatin (Carbo) act synergistically to significantly inhibit cell proliferation and DRP1 phosphorylation, reduce abundance of intermediates in pyrimidine de novo pathway, and increase apoptosis and DNA damage. Combination of Leflu&Carbo has anti-tumorigenic effect in vivo. Additionally, lurbinectedin (Lur) and Teri potently and synergistically inhibited spheroid growth and depleted uridine and DRP1 phosphorylation in mouse tumors. Our results suggest combinations of Carbo and Lur with Teri or Leflu are efficacious and underscore how the relationship between DRP1/DHODH and mitochondrial plasticity serves as a potential therapeutic target to validate these treatment strategies in SCLC clinical trials.